Eton Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
ETON$56.46+19.7%Stored close · as of Nov 6, 2026
Contents
Statements of Operations
(In thousands, except per share amounts)
| For the years ended | |||
|---|---|---|---|
| December 31, | December 31, | December 31, | |
| 2024 | 2023 | 2022 | |
| Revenues: | |||
| Licensing revenue | $500 | $5,500 | $10,000 |
| Product sales and royalties, net | 38,511 | 26,142 | 11,251 |
| Total net revenues | 39,011 | 31,642 | 21,251 |
| Cost of Sales: | |||
| Licensing revenue | 270 | 1,000 | 1,640 |
| Product sales and royalties | 15,330 | 9,581 | 5,293 |
| Total cost of sales | 15,600 | 10,581 | 6,933 |
| Gross profit | 23,411 | 21,061 | 14,318 |
| Operating expenses: | |||
| Research and development | 3,255 | 3,322 | 3,996 |
| General and administrative | 22,753 | 18,931 | 18,582 |
| Total operating expenses | 26,008 | 22,253 | 22,578 |
| Loss from operations | (2,597) | (1,192) | (8,260) |
| Other income (expense): | |||
| Interest and other (expense) income, net | (1,211) | 503 | (761) |
| Loss before income tax expense | (3,808) | (689) | (9,021) |
| Income tax expense | 15 | 247 | — |
| Net loss | $(3,823) | $(936) | $(9,021) |
| Net loss per share, basic and diluted | $(0.15) | $(0.04) | $(0.36) |
| Weighted average number of common shares outstanding, basic and diluted | 25,895 | 25,645 | 25,146 |
Eton Pharmaceuticals, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.